{"id":69419,"date":"2026-07-06T11:42:29","date_gmt":"2026-07-06T03:42:29","guid":{"rendered":"https:\/\/flcube.com\/?p=69419"},"modified":"2026-07-06T11:42:30","modified_gmt":"2026-07-06T03:42:30","slug":"sino-biopharmaceutical-submits-china-marketing-application-for-worlds-first-intra-incisional-long-acting-ropivacaine-analgesic","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69419","title":{"rendered":"Sino Biopharmaceutical Submits China Marketing Application for World&#8217;s First Intra-Incisional Long-Acting Ropivacaine Analgesic"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sino Biopharmaceutical Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>) announced that its subsidiary, <strong>Beijing Tide Pharmaceutical<\/strong>, has submitted a marketing application in China for <strong>Ropivacaine Hydrochloride Sustained-Release Solution<\/strong>, a <strong>Class 2.2 new drug<\/strong> developed for <strong>long-acting analgesia<\/strong> in adults. The product represents the <strong>world&#8217;s first long-acting ropivacaine analgesic<\/strong> administered via <strong>intra-incisional application<\/strong>, leveraging the company&#8217;s proprietary <strong>lipid-targeted injection technology platform<\/strong> to address significant unmet needs in postoperative pain management.<\/p>\n\n\n\n<h2 id=\"h-regulatory-amp-development-milestone\" class=\"wp-block-heading\">Regulatory &amp; Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Applicant<\/strong><\/td><td>Beijing Tide Pharmaceutical (subsidiary of Sino Biopharmaceutical HKG: 1177)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Ropivacaine Hydrochloride Sustained-Release Solution<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Class 2.2 new drug (China regulatory classification)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Long-acting analgesia in adults<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>Marketing authorization submission<\/td><\/tr><tr><td><strong>Submission Date<\/strong><\/td><td>03 Jul 2026<\/td><\/tr><tr><td><strong>Jurisdiction<\/strong><\/td><td>China (NMPA)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-innovation-amp-technology-platform\" class=\"wp-block-heading\">Product Innovation &amp; Technology Platform<\/h2>\n\n\n\n<h3 id=\"h-core-innovation\" class=\"wp-block-heading\">Core Innovation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>World&#8217;s First:<\/strong> Intra-incisional long-acting ropivacaine formulation<\/li>\n\n\n\n<li><strong>Technology Platform:<\/strong> Proprietary lipid-targeted injection technology<\/li>\n\n\n\n<li><strong>Drug Class:<\/strong> Non-opioid local anesthetic with sustained-release properties<\/li>\n\n\n\n<li><strong>Active Ingredient:<\/strong> Ropivacaine hydrochloride (established safety profile with extended duration)<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-administration-protocol\" class=\"wp-block-heading\">Administration Protocol<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Application Method:<\/strong> Applied directly into surgical incision before wound closure<\/li>\n\n\n\n<li><strong>Clinical Advantage:<\/strong> Simplified procedure requiring no additional steps post-surgery<\/li>\n\n\n\n<li><strong>Time Efficiency:<\/strong> Reduces healthcare provider time requirements compared to traditional postoperative pain management protocols<\/li>\n\n\n\n<li><strong>Patient Benefit:<\/strong> Continuous local analgesia without systemic opioid exposure<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Postoperative Pain Market:<\/strong> Global market valued at over $25 billion annually, with strong demand for non-opioid alternatives amid opioid crisis concerns<\/li>\n\n\n\n<li><strong>Current Standard of Care:<\/strong> Relies heavily on systemic opioids, NSAIDs, and short-acting local anesthetics requiring repeated administration<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong><\/li>\n\n\n\n<li><strong>Duration:<\/strong> Extended analgesic effect vs. conventional ropivacaine (hours vs. days)<\/li>\n\n\n\n<li><strong>Convenience:<\/strong> Single intra-operative application vs. multiple postoperative interventions<\/li>\n\n\n\n<li><strong>Safety:<\/strong> Local delivery minimizes systemic side effects associated with opioids<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Premium pricing opportunity in surgical settings across general surgery, orthopedics, and plastic surgery procedures<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-for-sino-biopharmaceutical\" class=\"wp-block-heading\">Strategic Implications for Sino Biopharmaceutical<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation:<\/strong> Successful approval would validate the lipid-targeted injection technology for other sustained-release applications<\/li>\n\n\n\n<li><strong>Market Leadership:<\/strong> First-mover advantage in intra-incisional long-acting analgesia segment<\/li>\n\n\n\n<li><strong>Revenue Diversification:<\/strong> Expands beyond oncology and biologics into high-volume surgical pain management<\/li>\n\n\n\n<li><strong>Global Expansion Potential:<\/strong> Strong foundation for international regulatory submissions following Chinese approval<\/li>\n\n\n\n<li><strong>Healthcare System Benefits:<\/strong> Potential to reduce hospital stays, decrease opioid prescriptions, and improve patient satisfaction scores<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The marketing application submission represents a critical milestone in bringing this innovative pain management solution to Chinese patients and healthcare providers, addressing both clinical efficacy and procedural efficiency in postoperative care.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070300919_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026070300919_c.\"><\/object><a id=\"wp-block-file--media-e56ee14f-fe22-4e18-ab19-e561b4baa626\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070300919_c.pdf\">2026070300919_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070300919_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e56ee14f-fe22-4e18-ab19-e561b4baa626\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Beijing Tide Pharmaceutical, has submitted a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[908,38,313,3531],"class_list":["post-69419","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-hkg-1177","tag-market-approval-filings","tag-sino-biopharmaceutical","tag-tide-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharmaceutical Submits China Marketing Application for World&#039;s First Intra-Incisional Long-Acting Ropivacaine Analgesic - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Beijing Tide Pharmaceutical, has submitted a marketing application in China for Ropivacaine Hydrochloride Sustained-Release Solution, a Class 2.2 new drug developed for long-acting analgesia in adults. The product represents the world&#039;s first long-acting ropivacaine analgesic administered via intra-incisional application, leveraging the company&#039;s proprietary lipid-targeted injection technology platform to address significant unmet needs in postoperative pain management.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69419\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharmaceutical Submits China Marketing Application for World&#039;s First Intra-Incisional Long-Acting Ropivacaine Analgesic\" \/>\n<meta property=\"og:description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Beijing Tide Pharmaceutical, has submitted a marketing application in China for Ropivacaine Hydrochloride Sustained-Release Solution, a Class 2.2 new drug developed for long-acting analgesia in adults. The product represents the world&#039;s first long-acting ropivacaine analgesic administered via intra-incisional application, leveraging the company&#039;s proprietary lipid-targeted injection technology platform to address significant unmet needs in postoperative pain management.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69419\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-06T03:42:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-06T03:42:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69419#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69419\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharmaceutical Submits China Marketing Application for World&#8217;s First Intra-Incisional Long-Acting Ropivacaine Analgesic\",\"datePublished\":\"2026-07-06T03:42:29+00:00\",\"dateModified\":\"2026-07-06T03:42:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69419\"},\"wordCount\":397,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 1177\",\"Market approval filings\",\"Sino Biopharmaceutical\",\"Tide Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69419#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69419\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69419\",\"name\":\"Sino Biopharmaceutical Submits China Marketing Application for World's First Intra-Incisional Long-Acting Ropivacaine Analgesic - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-06T03:42:29+00:00\",\"dateModified\":\"2026-07-06T03:42:30+00:00\",\"description\":\"Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Beijing Tide Pharmaceutical, has submitted a marketing application in China for Ropivacaine Hydrochloride Sustained-Release Solution, a Class 2.2 new drug developed for long-acting analgesia in adults. The product represents the world's first long-acting ropivacaine analgesic administered via intra-incisional application, leveraging the company's proprietary lipid-targeted injection technology platform to address significant unmet needs in postoperative pain management.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69419#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69419\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69419#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharmaceutical Submits China Marketing Application for World&#8217;s First Intra-Incisional Long-Acting Ropivacaine Analgesic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharmaceutical Submits China Marketing Application for World's First Intra-Incisional Long-Acting Ropivacaine Analgesic - Insight, China&#039;s Pharmaceutical Industry","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Beijing Tide Pharmaceutical, has submitted a marketing application in China for Ropivacaine Hydrochloride Sustained-Release Solution, a Class 2.2 new drug developed for long-acting analgesia in adults. The product represents the world's first long-acting ropivacaine analgesic administered via intra-incisional application, leveraging the company's proprietary lipid-targeted injection technology platform to address significant unmet needs in postoperative pain management.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69419","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharmaceutical Submits China Marketing Application for World's First Intra-Incisional Long-Acting Ropivacaine Analgesic","og_description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Beijing Tide Pharmaceutical, has submitted a marketing application in China for Ropivacaine Hydrochloride Sustained-Release Solution, a Class 2.2 new drug developed for long-acting analgesia in adults. The product represents the world's first long-acting ropivacaine analgesic administered via intra-incisional application, leveraging the company's proprietary lipid-targeted injection technology platform to address significant unmet needs in postoperative pain management.","og_url":"https:\/\/flcube.com\/?p=69419","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-06T03:42:29+00:00","article_modified_time":"2026-07-06T03:42:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69419#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69419"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharmaceutical Submits China Marketing Application for World&#8217;s First Intra-Incisional Long-Acting Ropivacaine Analgesic","datePublished":"2026-07-06T03:42:29+00:00","dateModified":"2026-07-06T03:42:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69419"},"wordCount":397,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 1177","Market approval filings","Sino Biopharmaceutical","Tide Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69419#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69419","url":"https:\/\/flcube.com\/?p=69419","name":"Sino Biopharmaceutical Submits China Marketing Application for World's First Intra-Incisional Long-Acting Ropivacaine Analgesic - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-06T03:42:29+00:00","dateModified":"2026-07-06T03:42:30+00:00","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Beijing Tide Pharmaceutical, has submitted a marketing application in China for Ropivacaine Hydrochloride Sustained-Release Solution, a Class 2.2 new drug developed for long-acting analgesia in adults. The product represents the world's first long-acting ropivacaine analgesic administered via intra-incisional application, leveraging the company's proprietary lipid-targeted injection technology platform to address significant unmet needs in postoperative pain management.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69419#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69419"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69419#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharmaceutical Submits China Marketing Application for World&#8217;s First Intra-Incisional Long-Acting Ropivacaine Analgesic"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69419"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69419\/revisions"}],"predecessor-version":[{"id":69421,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69419\/revisions\/69421"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}